| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1018939228201 |
| P698 | PubMed publication ID | 7686672 |
| P2093 | author name string | C. R. Middaugh | |
| M. Keogan | |||
| K. C. Thompson | |||
| J. V. Bondi | |||
| J. M. Dabora | |||
| M. W. Bruner | |||
| P. K. Tsai | |||
| D. B. Volkin | |||
| J. O. Gress | |||
| B. Matuszewska | |||
| P2860 | cites work | Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan | Q42800314 |
| Nature of the interaction of growth factors with suramin | Q42816405 | ||
| Beta-II conformation of all-beta proteins can be distinguished from unordered form by circular dichroism | Q44370059 | ||
| Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro | Q44656846 | ||
| Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation | Q48470111 | ||
| Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor | Q67684669 | ||
| Effect of polyanions on the refolding of human acidic fibroblast growth factor | Q67705851 | ||
| Heparin protects basic and acidic FGF from inactivation | Q68895706 | ||
| Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro | Q69723398 | ||
| Stabilizing basic fibroblast growth factor using protein engineering | Q69821287 | ||
| Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound healing model | Q71615454 | ||
| Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta | Q24563285 | ||
| Three-dimensional structure of human basic fibroblast growth factor | Q24563295 | ||
| Crystal structure of basic fibroblast growth factor at 1.6 A resolution | Q27647318 | ||
| Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors | Q28267322 | ||
| The structure of human acidic fibroblast growth factor and its interaction with heparin | Q33266596 | ||
| A differential scanning calorimetric study of the bovine lens crystallins | Q34482405 | ||
| PDGF and FGF stimulate wound healing in the genetically diabetic mouse | Q35811771 | ||
| Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation | Q36219245 | ||
| Extracellular matrix-resident basic fibroblast growth factor: Implication for the control of angiogenesis | Q36657969 | ||
| Structure-Function Studies of Acidic Fibroblast Growth Factor | Q36713232 | ||
| Direct effect of basic fibroblast growth factor on gene transcription in a cell-free system | Q37049994 | ||
| The heparin-binding (fibroblast) growth factor family of proteins | Q38286731 | ||
| Nature of the interaction of heparin with acidic fibroblast growth factor | Q38319104 | ||
| Physical stabilization of acidic fibroblast growth factor by polyanions | Q38323279 | ||
| The stabilization of proteins by sucrose | Q38356178 | ||
| Disulfide Bonds are Neither Required, Present, Nor Compatible with Full Activity of Human Recombinant Acidic Fibroblast Growth Factor | Q41757013 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 649-659 | |
| P577 | publication date | 1993-05-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Formulation design of acidic fibroblast growth factor | |
| P478 | volume | 10 |
| Q30356926 | A network-based analysis of polyanion-binding proteins utilizing yeast protein arrays. |
| Q45988445 | A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor. |
| Q46927988 | A practical guide on how osmolytes modulate macromolecular properties. |
| Q53537715 | Accelerated healing in NONcNZO10/LtJ type 2 diabetic mice by FGF-1. |
| Q71615454 | Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound healing model |
| Q72579183 | Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization |
| Q38290536 | An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities |
| Q41905086 | An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1. |
| Q51552286 | An investigation of the long-term bioactivity of endogenous growth factor in OASIS Wound Matrix. |
| Q35184855 | Biodegradable microspheres for protein delivery |
| Q37694861 | Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis |
| Q42824665 | Calcium sulfate spinal cord scaffold: a study on degradation and fibroblast growth factor 1 loading and release |
| Q46259884 | Factors affecting the physical stability (aggregation) of peptide therapeutics |
| Q83279627 | Folding considerations for therapeutic protein formulations |
| Q34041339 | Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution |
| Q38553307 | Improving protein therapeutics with sustained-release formulations |
| Q36951646 | Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice |
| Q33719192 | Instability, stabilization, and formulation of liquid protein pharmaceuticals |
| Q36950922 | Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity |
| Q74383152 | Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry |
| Q36974181 | Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII) |
| Q73761304 | Liposomes as formulation excipients for protein pharmaceuticals: a model protein study |
| Q44583820 | Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin |
| Q36970547 | Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex |
| Q36232650 | Past, present, and future technologies for oral delivery of therapeutic proteins |
| Q34469627 | Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application |
| Q36951699 | Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. |
| Q35563682 | Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation |
| Q35773099 | Polyanions and the proteome |
| Q42033434 | Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design |
| Q26998787 | Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles |
| Q74136537 | Recombinant factor VIII SQ--stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue |
| Q34170878 | Reversible thermal denaturation of human FGF-1 induced by low concentrations of guanidine hydrochloride |
| Q47303940 | Size exclusion HPLC method for the determination of acidic fibroblast growth factor in viscous formulations |
| Q37689616 | Stability of protein pharmaceuticals: an update |
| Q71744528 | Stabilization of recombinant human keratinocyte growth factor by osmolytes and salts |
| Q46496805 | Stabilization of somatropin by heparin |
| Q27636303 | Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β-trefoil |
| Q38314372 | Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor |
| Q77214878 | Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions |
| Q80548126 | Use of biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: evaluation of suitable purification process conditions |
Search more.